Currently out of the existing stock ratings of Brooks O'neil, 107 are a BUY (93.04%), 8 are a HOLD (6.96%).

Brooks O'neil

Work Performance Price Targets & Ratings Chart

Analyst Brooks O'neil, currently employed at LAKE STREET, carries an average stock price target met ratio of 46.65% that have a potential upside of 33.82% achieved within 174 days.

Brooks O'neil’s has documented 250 price targets and ratings displayed on 31 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on PIII, P3 Health Partners at 28-Aug-2025.

Wall Street Analyst Brooks O'neil

Analyst best performing recommendations are on CCRN (CROSS COUNTRY HEALTHCARE).
The best stock recommendation documented was for SMLR (SEMLER SCIENTIFIC) at 7/30/2018. The price target of $22 was fulfilled within 3 days with a profit of $4.5 (25.71%) receiving and performance score of 85.71.

Average potential price target upside

of $26.08 (44.28%) on TNDM (TANDEM DIABETES CARE).
of $21.77 (66.1%) on SMLR (SEMLER SCIENTIFIC).
of $19.38 (18.98%) on SIEN (SIENTRA).

ATEC Alphatec Holdings CSII Cardiovascular Systems JYNT The Joint Corp KIN Kindred Biosciences LMAT LeMaitre Vascular OPCH Option Care Health SMLR Semler Scientific SRDX SurModics SRGA Surgalign Holdings TNDM Tandem Diabetes Care AMEH Apollo Medical Holdings ARAY Accuray DPLO Diplomat Pharmacy DYNT Dynatronics ELMD Electromed HROW Harrow Health INFU InfuSystems Holdings SIEN Sientra RCEL Avita Medical Ltd ICAD icad inc AUGX Augmedix STRM Streamline Health Solutions MODV ModivCare PIII P3 Health Partners NUWE Nuwellis AMN AMN Healthcare Services AORT Artivion CCRN Cross Country Healthcare CRY CryoLife LFMD LifeMD VMD Viemed Healthcare

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Matt Miksic (BARCLAYS)